申请人:Neurogen Corporation.
公开号:US20020128274A1
公开(公告)日:2002-09-12
Disclosed are benzylpiperazinyl-indolinylethanone compounds which are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents. Pharmaceutical compositions, including packaged pharmaceutical compositions, are further provided. Compounds of the invention are also useful as probes for the localization of GABA
A
receptors in tissue samples.
揭示了苯甲基哌嗪基吲哚基乙酮类化合物,其可用于治疗和/或预防神经心理障碍,包括但不限于精神分裂症、狂躁症、痴呆、抑郁症、焦虑症、强迫行为、物质滥用、帕金森病样运动障碍和与神经阻滞剂使用相关的运动障碍。此外,还提供了制药组合物,包括包装的制药组合物。该发明的化合物还可用作组织样本中GABAA受体的定位探针。